154 related articles for article (PubMed ID: 15906354)
1. TP53 alterations and patterns of carcinogen exposure in a U.S. population-based study of bladder cancer.
Kelsey KT; Hirao T; Hirao S; Devi-Ashok T; Nelson HH; Andrew A; Colt J; Baris D; Morris JS; Schned A; Karagas M
Int J Cancer; 2005 Nov; 117(3):370-5. PubMed ID: 15906354
[TBL] [Abstract][Full Text] [Related]
2. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.
Wallerand H; Bakkar AA; de Medina SG; Pairon JC; Yang YC; Vordos D; Bittard H; Fauconnet S; Kouyoumdjian JC; Jaurand MC; Zhang ZF; Radvanyi F; Thiery JP; Chopin DK
Carcinogenesis; 2005 Jan; 26(1):177-84. PubMed ID: 15347601
[TBL] [Abstract][Full Text] [Related]
3. Carcinogen exposure and gene promoter hypermethylation in bladder cancer.
Marsit CJ; Karagas MR; Danaee H; Liu M; Andrew A; Schned A; Nelson HH; Kelsey KT
Carcinogenesis; 2006 Jan; 27(1):112-6. PubMed ID: 15987713
[TBL] [Abstract][Full Text] [Related]
4. Tobacco smoking, occupation, and p53 nuclear overexpression in early stage bladder cancer.
Zhang ZF; Sarkis AS; Cordon-Cardo C; Dalbagni G; Melamed J; Aprikian A; Pollack D; Sheinfeld J; Herr HW; Fair WR
Cancer Epidemiol Biomarkers Prev; 1994; 3(1):19-24. PubMed ID: 8118380
[TBL] [Abstract][Full Text] [Related]
5. Cigarette smoking and chromosome 9 alterations in bladder cancer.
Zhang ZF; Shu XM; Cordon-Cardo C; Orlow I; Lu ML; Millon TV; Cao PQ; Connolly-Jenks C; Dalbagni G; Lianes P; Lacombe L; Reuter VE; Scher H
Cancer Epidemiol Biomarkers Prev; 1997 May; 6(5):321-6. PubMed ID: 9149891
[TBL] [Abstract][Full Text] [Related]
6. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
7. FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.
Smal MP; Rolevich AI; Polyakov SL; Krasny SA; Goncharova RI
Exp Oncol; 2014 Dec; 36(4):246-51. PubMed ID: 25537218
[TBL] [Abstract][Full Text] [Related]
8. Carcinogen exposure and epigenetic silencing in bladder cancer.
Marsit CJ; Karagas MR; Schned A; Kelsey KT
Ann N Y Acad Sci; 2006 Sep; 1076():810-21. PubMed ID: 17119258
[TBL] [Abstract][Full Text] [Related]
9. TP53 mutations in workers exposed to occupational carcinogens.
Vähäkangas K
Hum Mutat; 2003 Mar; 21(3):240-51. PubMed ID: 12619109
[TBL] [Abstract][Full Text] [Related]
10. Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer.
Ecke TH; Schlechte HH; Gunia S; Lenk SV; Loening SA
Urol Oncol; 2008; 26(5):470-3. PubMed ID: 18367114
[TBL] [Abstract][Full Text] [Related]
11. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer.
Olivier M; Hussain SP; Caron de Fromentel C; Hainaut P; Harris CC
IARC Sci Publ; 2004; (157):247-70. PubMed ID: 15055300
[TBL] [Abstract][Full Text] [Related]
12. Specific-mutational patterns of p53 gene in bladder transitional cell carcinoma among a group of Iraqi patients exposed to war environmental hazards.
Al-Kashwan TA; Houshmand M; Al-Janabi A; Melconian AK; Al-Abbasi D; Al-Musawi MN; Rostami M; Yasseen AA
BMC Res Notes; 2012 Aug; 5():466. PubMed ID: 22929185
[TBL] [Abstract][Full Text] [Related]
13. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.
Markl ID; Jones PA
Cancer Res; 1998 Dec; 58(23):5348-53. PubMed ID: 9850064
[TBL] [Abstract][Full Text] [Related]
14. TP53 intronic mutations in bovine enzootic hematuria-associated urinary bladder tumors.
Sasani F; Baghban F; Nikbakht Brujeni GH; Kazemi M
Vet Pathol; 2013 May; 50(3):543-7. PubMed ID: 23242803
[TBL] [Abstract][Full Text] [Related]
15. Analysis of 4-ABP-DNA adducts and p53 alterations in urinary bladder carcinoma.
Romano G; Garagnani L; Boninsegna A; Ferrari P; Flamini G; De Gaetani C; Sgambato A; Giovanni F; Curigliano G; Ferretti G; Cittadini A; Trentini G
Anticancer Res; 1999; 19(5C):4571-6. PubMed ID: 10650812
[TBL] [Abstract][Full Text] [Related]
16. p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors.
Schroeder JC; Conway K; Li Y; Mistry K; Bell DA; Taylor JA
Cancer Res; 2003 Nov; 63(21):7530-8. PubMed ID: 14612556
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer.
Marsit CJ; Karagas MR; Andrew A; Liu M; Danaee H; Schned AR; Nelson HH; Kelsey KT
Cancer Res; 2005 Aug; 65(16):7081-5. PubMed ID: 16103055
[TBL] [Abstract][Full Text] [Related]
18. A molecular and epidemiological study on bladder cancer: p53 mutations, tobacco smoking, and occupational exposure to asbestos.
Kannio A; Ridanpää M; Koskinen H; Partanen T; Anttila S; Collan Y; Hietanen E; Vainio H; Husgafvel-Pursiainen K
Cancer Epidemiol Biomarkers Prev; 1996 Jan; 5(1):33-9. PubMed ID: 8770464
[TBL] [Abstract][Full Text] [Related]
19. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.
Dahse R; Utting M; Werner W; Schimmel B; Claussen U; Junker K
Int J Oncol; 2002 Jan; 20(1):107-15. PubMed ID: 11743649
[TBL] [Abstract][Full Text] [Related]
20. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
